GLP1R and obesity due to melanocortin 4 receptor deficiency: Firstly, tirzepatide results in greater WL and HbA1c reduction than other GLP‐1 based therapies, even at the dose of 5 mg once weekly (the lowest approved dose for obesity and T2D management).50